TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23604626

Group type: EXPERIMENTAL
Intervention: Synchronous audiovisual stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asynchronous audiovisual stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimodal cuing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective judgment of simultaneity
Number of subjects: 0
Study: 21484237

Group type: EXPERIMENTAL
Intervention: 120 mg of hydrocortisone (two boluses of 60 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone (DEX)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19057376

Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/d
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/d
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 17715647

Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone processing mode
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Directional microphone processing mode
Number of subjects: 2

Group type: COMPARATOR
Intervention: Environmental recordings presented in laboratory setting
Number of subjects: 2
Study: 15076259

Group type: EXPERIMENTAL
Intervention: Osmotic, controlled-release oral system (OROS) MPH (Concerta) given once daily (q.d.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Immediate-release MPH (Ritalin) given in equal doses three times daily (t.i.d.)
Number of subjects: 6
Study: 11302799

Group type: EXPERIMENTAL
Intervention: +Calanolide A (200 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: +Calanolide A (400 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: +Calanolide A (600 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: +Calanolide A (800 mg)
Number of subjects: 47
Study: 9499204

Group type: EXPERIMENTAL
Intervention: PstI polymorphism at the ACE locus in NIDDM patients with diabetic nephropathy (n = 140)
Number of subjects: 220

Group type: COMPARATOR
Intervention: PstI polymorphism at the ACE locus in normoalbuminuric control subjects (n = 80)
Number of subjects: 220
Study: 7880510

Group type: EXPERIMENTAL
Intervention: Benzodiazepine agonists (midazolam 2.5 mg or diazepam 5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiopental sodium 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nondepolarizing muscle relaxants (atracurium 40 micrograms/kg or metocurine 50 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 0
Study: 3207438

Group type: EXPERIMENTAL
Intervention: Ciclotropium bromide (CTB) administered intravenously
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HNB) administered intravenously
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ciclotropium bromide (CTB)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (HNB)
Number of subjects: 10
Study: 29336700

Group type: EXPERIMENTAL
Intervention: Soy protein supplement (SPS) 45g (230 Kcal) added to lunch fruit juice
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (fruit juice without SPS)
Number of subjects: 107
Study: 28612083

Group type: EXPERIMENTAL
Intervention: Combination therapy (tamsulosin 0.2 mg/day and trospium chloride 20 mg twice daily)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Monotherapy (tamsulosin 0.2 mg/day)
Number of subjects: 124
Study: 26317858

Group type: EXPERIMENTAL
Intervention: Pain exposure group (prior exposure to the same pain stimulus)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Touch exposure group (no prior exposure to pain stimulus)
Number of subjects: 62
Study: 23343197

Group type: EXPERIMENTAL
Intervention: Early intensive cognitive-linguistic therapy (Group A) - one hour a day for four weeks, starting within two weeks after stroke.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Deferred regular therapy (Group B) - professional speech and language therapy deferred for four weeks, followed by conventional therapy.
Number of subjects: 150
Study: 20435447

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 232
Study: 19085499

Group type: EXPERIMENTAL
Intervention: Compression bandage
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-compression bandage
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 16611657

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b) administered subcutaneously thrice weekly for 2 years
Number of subjects: 50

Group type: COMPARATOR
Intervention: Colchicine for 2 years
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (IFN-gamma 1b) and Colchicine
Number of subjects: 50
Study: 12868555

Group type: EXPERIMENTAL
Intervention: Irinotecan 125 mg/m2 and mitomycin C 5 mg/m2, given every 2 weeks until progression or limiting toxicity.
Number of subjects: 40
Study: 11152253

Group type: EXPERIMENTAL
Intervention: Retention sutures (n = 44)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional mass closure without retention sutures (n = 51)
Number of subjects: 95
Study: 9183137

Group type: EXPERIMENTAL
Intervention: Active treatment (1 hour of bright-light therapy plus 2 hours of dawn simulation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (1 hour of clear goggles plus 5 minutes of low-intensity dawn simulation)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 28
Study: 1550435

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 micrograms/min of isosorbide dinitrate (ISDN)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine at a dosage of 10 g/24 hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3902224

Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg single oral dose)
Number of subjects: 12
Study: 30482631

Group type: EXPERIMENTAL
Intervention: Metacognitive group intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 27814706

Group type: EXPERIMENTAL
Intervention: Nurse-led empowerment counselling intervention (two 30-min counselling sessions)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Enhanced control condition (a referral list)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Nurse-led empowerment counselling intervention
Number of subjects: 504
Study: 25099748

Group type: EXPERIMENTAL
Intervention: Proximal sciatic nerve block (SNB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distal sciatic nerve block (SNB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No sciatic nerve block (Placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Proximal and distal sciatic nerve block (SNB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Popliteal technique (Distal SNB)
Number of subjects: 60
Study: 22515528

Group type: EXPERIMENTAL
Intervention: Telephone-based interpersonal psychotherapy (IPT) sessions (12 sessions within 12 to 16 weeks, provided by trained nurses)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard postpartum care
Number of subjects: 240
Study: 21207798

Group type: EXPERIMENTAL
Intervention: 9.5% hydrogen peroxide high-adhesion whitening strips
Number of subjects: 44

Group type: COMPARATOR
Intervention: 6.5% hydrogen peroxide professional whitening strips
Number of subjects: 44
Study: 18425248

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-fluoride dentifrice (PD)
Number of subjects: 10
Study: 15832421

Group type: EXPERIMENTAL
Intervention: OAC group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: OAM group (omeprazole 20 mg, amoxicillin 1000 mg, metronidazole 400 mg)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: OAC group
Number of subjects: 103

Group type: COMPARATOR
Intervention: OAM group
Number of subjects: 103
Study: 12953127

Group type: EXPERIMENTAL
Intervention: 10 microg/kg/day (single dose) G-CSF
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2 x 5 microg/kg/day (split dose) G-CSF
Number of subjects: 28
Study: 10638992

Group type: EXPERIMENTAL
Intervention: D2 surgery (radical surgery)
Number of subjects: 400

Group type: COMPARATOR
Intervention: D1 surgery (conventional surgery)
Number of subjects: 400
Study: 8650638

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1389955

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 10
Study: 6598018

Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 32
Study: 30650624

Group type: EXPERIMENTAL
Intervention: Multidimensional physical activity intervention (twice a week for 10 weeks)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 746
Study: 29888845

Group type: EXPERIMENTAL
Intervention: QuinteT Recruitment Intervention (QRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard recruitment methods without QRI
Number of subjects: 0
Study: 27869410

Group type: EXPERIMENTAL
Intervention: Strength training using flexible Thera-band elastic exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine exercises in physical education class
Number of subjects: 30
Study: 24853262

Group type: EXPERIMENTAL
Intervention: Tan EndoGlide
Number of subjects: 20

Group type: COMPARATOR
Intervention: EndoSerter
Number of subjects: 20
Study: 22768272

Group type: EXPERIMENTAL
Intervention: Daytime energy intake of ∼150% of estimated daily energy expenditure
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Daytime energy intake of ∼50% of estimated daily energy expenditure
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sleep deprivation (SD) with energy oversupply
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sleep deprivation (SD)
Number of subjects: 14
Study: 20455296

Group type: EXPERIMENTAL
Intervention: New broader framework for evaluating clinical practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard for evaluating evidence
Number of subjects: 0
Study: 17868007

Group type: EXPERIMENTAL
Intervention: Extended-release dipyridamole plus aspirin
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Telmisartan in addition to usual care
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Safety evaluation
Number of subjects: 20000
Study: 11260535

Group type: EXPERIMENTAL
Intervention: 1.0 mg nickel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.0 mg nickel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 30
Study: 9030805

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (37 degrees C, n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (28 degrees C, n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (Normothermic and Hypothermic)
Number of subjects: 34
Study: 8391064

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus thoracic radiotherapy (TRT)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Chemotherapy alone (CAV)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (cisplatin and etoposide)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Observation after CAV
Number of subjects: 386
Study: 3555049

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg orally, twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cinoxacin (500 mg orally, twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Cinoxacin
Number of subjects: 60
Study: 29872966

Group type: EXPERIMENTAL
Intervention: Preoperative forced-air warming using BairPaws™ system for at least 30 min
Number of subjects: 200

Group type: COMPARATOR
Intervention: Warmed blankets on request (Control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Preoperative forced-air warming
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (Warmed blankets)
Number of subjects: 200
Study: 27363482

Group type: EXPERIMENTAL
Intervention: Web‐based self‐help for SI
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study: 24706369

Group type: EXPERIMENTAL
Intervention: Emergency telephone consultations with simulated patients (SPs)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Advice to call for an ambulance in ETCs
Number of subjects: 137
Study: 23453352

Group type: EXPERIMENTAL
Intervention: Glucomannan (GM) combined with low-dose chromium-polynicotinate (CP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Glucomannan (GM) combined with low-dose policosanol (PC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Glucomannan (GM) with resistant starch (control)
Number of subjects: 120
Study: 20636352

Group type: COMPARATOR
Intervention: K-Flexofile instruments and Gates Glidden drills
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: V-Taper Ni-Ti rotary and stainless steel hand instruments
Number of subjects: 40
Study: 19026310

Group type: EXPERIMENTAL
Intervention: High dose steroids and cyclosporine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Muromonab-CD3
Number of subjects: 20
Study: 16738915

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Microfracture technique (MFR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal cartilage
Number of subjects: 27
Study: 12523327

Group type: EXPERIMENTAL
Intervention: LCD group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 11086179

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 36 mg/m2 on day 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 45 mg/m2 on day 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 60 mg/m2 on day 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 75 mg/m2 on day 1 with cytarabine 500 mg/m2 and etoposide 200 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EMA chemotherapy (mitoxantrone, cytarabine, etoposide)
Number of subjects: 24
Study: 8804872

Group type: EXPERIMENTAL
Intervention: Glutamine glucose salt solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Alanine glucose salt solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glucose alone
Number of subjects: 19
Study: 1733435

Group type: EXPERIMENTAL
Intervention: 12-week chemohormonal regimen (cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin, tamoxifen)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 36 weeks of CMFVP
Number of subjects: 122
Study: 31454561

Group type: EXPERIMENTAL
Intervention: BENECA mHealth and rehabilitation for 2 months (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: BENECA mHealth alone (n=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BENECA mHealth and rehabilitation
Number of subjects: 80
Study: 29886769

Group type: EXPERIMENTAL
Intervention: Activity restriction for more than a week
Number of subjects: 1426

Group type: COMPARATOR
Intervention: No activity restriction
Number of subjects: 1426
Study: 28245352

Group type: EXPERIMENTAL
Intervention: Flortec (probiotic with prebiotic)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control substance (starch)
Number of subjects: 41
Study: 26346868

Group type: EXPERIMENTAL
Intervention: On-site cytopathology evaluation (OCE+) during EUS-FNA
Number of subjects: 241

Group type: COMPARATOR
Intervention: No on-site cytopathology evaluation (OCE-) during EUS-FNA
Number of subjects: 241
Study: 24681963

Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: montelukast
Number of subjects: 80
Study: 22859902

Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL of nonparticulate betamethasone
Number of subjects: 120
Study: 19363182

Group type: EXPERIMENTAL
Intervention: Full intervention group (access to test results and learning activities)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Partial intervention group (access to diagnostic tests results)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Partial intervention group (access to learning activities)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Control group (business as usual)
Number of subjects: 905
Study: 18404664

Group type: EXPERIMENTAL
Intervention: 1-week recall period
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-day recall period
Number of subjects: 0
Study: 16231263

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation with dietary and exercise counseling
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dietary and exercise counseling alone
Number of subjects: 52
Study: 12421058

Group type: EXPERIMENTAL
Intervention: Moving objects depicted as transparent, opaque, or black cubes moving parallel to or intersecting the observer's path.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated observer movement over a ground plane.
Number of subjects: 0
Study: 10349586

Group type: EXPERIMENTAL
Intervention: High school athletes
Number of subjects: 678

Group type: COMPARATOR
Intervention: Nonathletes
Number of subjects: 678
Study: 8953684

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 1.5-2.0 g/day
Number of subjects: 515

Group type: COMPARATOR
Intervention: cefuroxime 3.0-4.5 g/day plus metronidazole 1.0-1.5 g/day
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study: 2007851

Group type: EXPERIMENTAL
Intervention: Endotoxin/ibuprofen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endotoxin alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endotoxin/pentoxifylline
Number of subjects: 25
Study: 6211753

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (100 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31488103

Group type: EXPERIMENTAL
Intervention: VR SCT (DiSCoVR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: VR relaxation training (VRelax; active control)
Number of subjects: 100
Study: 27628742

Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Parent‐Focused Treatment (PFT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CLAS and PFT
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CLAS
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: PFT
Number of subjects: 199
Study: 26021246

Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg bid for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ranolazine)
Number of subjects: 40
Study: 24980066

Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 23129778

Group type: EXPERIMENTAL
Intervention: Ki-67 index guided preoperative chemotherapy (paclitaxel and trastuzumab initially, modified based on Ki-67 index)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard preoperative chemotherapy (paclitaxel and trastuzumab)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ki-67 index guided preoperative chemotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard preoperative chemotherapy
Number of subjects: 200
Study: 19387404

Group type: EXPERIMENTAL
Intervention: Elastic Band (EB)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Weighted Chain (WC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study: 17352304

Group type: EXPERIMENTAL
Intervention: Testing for thrombophilia and receiving test results
Number of subjects: 1336

Group type: COMPARATOR
Intervention: Testing for thrombophilia but not disclosing results
Number of subjects: 1336

Group type: EXPERIMENTAL
Intervention: Additional anticoagulant treatment for patients found to have thrombophilia
Number of subjects: 1336

Group type: COMPARATOR
Intervention: Standard predefined duration of treatment for others
Number of subjects: 1336
Study: 15531034

Group type: EXPERIMENTAL
Intervention: HPV16 Immunotherapeutic (HPV16 E6E7 fusion protein and ISCOMATRIX adjuvant)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HPV16 Immunotherapeutic
Number of subjects: 31
Study: 11417762

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine with indinavir added from week 12
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Stavudine/lamivudine with indinavir added from week 12
Number of subjects: 47

Group type: COMPARATOR
Intervention: Zidovudine/lamivudine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Stavudine/lamivudine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CSF HIV-1 RNA levels
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CSF indinavir concentration
Number of subjects: 47
Study: 9792572

Group type: EXPERIMENTAL
Intervention: LT receptor antagonist (pranlukast, 450 mg/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TXA2 synthetase inhibitor (ozagrel, 800 mg/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TXA2 receptor antagonist (seratrodast, 80 mg/d)
Number of subjects: 6
Study: 7825976

Group type: EXPERIMENTAL
Intervention: melphalan alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: melphalan combined with total body irradiation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: busulphan plus melphalan
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BEAM association (BCNU + etoposide + high dose aracytine + high dose melphalan)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: all patients
Number of subjects: 20